Paola Papaldo

2.7k total citations
66 papers, 1.7k citations indexed

About

Paola Papaldo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Paola Papaldo has authored 66 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Paola Papaldo's work include Cancer Treatment and Pharmacology (36 papers), HER2/EGFR in Cancer Research (24 papers) and Breast Cancer Treatment Studies (16 papers). Paola Papaldo is often cited by papers focused on Cancer Treatment and Pharmacology (36 papers), HER2/EGFR in Cancer Research (24 papers) and Breast Cancer Treatment Studies (16 papers). Paola Papaldo collaborates with scholars based in Italy, United States and Malaysia. Paola Papaldo's co-authors include Alessandra Fabi, G. Ferretti, Francesco Cognetti, Paolo Carlini, Serena Di Cosimo, Diana Giannarelli, Luigi Di Lauro, Massimo Lopez, Marcella Mottolese and Alessandra Felici and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Paola Papaldo

63 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paola Papaldo Italy	25	1.1k	439	411	336	236	66	1.7k
Laura Pizzuti Italy	23	906 0.8×	410 0.9×	454 1.1×	333 1.0×	119 0.5×	96	1.7k
Cecilia Nisticò Italy	23	1.2k 1.1×	555 1.3×	306 0.7×	403 1.2×	166 0.7×	70	1.6k
Mariantonietta Colozza Italy	19	1.0k 0.9×	472 1.1×	360 0.9×	304 0.9×	233 1.0×	36	1.4k
Enrico Ricevuto Italy	24	942 0.9×	379 0.9×	623 1.5×	465 1.4×	129 0.5×	121	2.0k
Luigi Di Lauro Italy	25	886 0.8×	328 0.7×	398 1.0×	307 0.9×	58 0.2×	113	1.7k
Yasuo Hozumi Japan	23	964 0.9×	704 1.6×	328 0.8×	522 1.6×	156 0.7×	84	1.9k
Kristi A. Boehm United States	24	1.5k 1.3×	720 1.6×	495 1.2×	736 2.2×	117 0.5×	77	2.3k
Massimo Lopez Italy	21	1.6k 1.4×	516 1.2×	405 1.0×	598 1.8×	49 0.2×	59	2.2k
D. Frye United States	12	1.5k 1.3×	708 1.6×	304 0.7×	401 1.2×	97 0.4×	22	1.9k
M.E.L. van der Burg Netherlands	27	961 0.9×	187 0.4×	452 1.1×	417 1.2×	100 0.4×	69	2.4k

Countries citing papers authored by Paola Papaldo

Since Specialization

Citations

This map shows the geographic impact of Paola Papaldo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paola Papaldo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paola Papaldo more than expected).

Fields of papers citing papers by Paola Papaldo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paola Papaldo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paola Papaldo. The network helps show where Paola Papaldo may publish in the future.

Co-authorship network of co-authors of Paola Papaldo

This figure shows the co-authorship network connecting the top 25 collaborators of Paola Papaldo. A scholar is included among the top collaborators of Paola Papaldo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paola Papaldo. Paola Papaldo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fabi, Alessandra, G. Ferretti, Paola Malaguti, et al.. (2020). Nanoparticle Albumin-Bound Paclitaxel/Liposomal-Encapsulated Doxorubicin in HER2-Negative Metastatic Breast Cancer Patients. Future Oncology. 16(22). 1631–1639. 10 indexed citations

Giannarelli, Diana, G. Ferretti, Alessandra Fabi, et al.. (2015). Dose-finding study on a continuous dose of oral vinorelbine (VNR) in heavily pre-treated metastatic breast cancer (MBC) patients (pts). Annals of Oncology. 26. vi15–vi15.

Fabi, Alessandra, Diana Giannarelli, Paola Malaguti, et al.. (2015). Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Drug Design Development and Therapy. 9. 6177–6177. 22 indexed citations

Fabi, Alessandra, Roberta Merola, G. Ferretti, et al.. (2013). Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert Opinion on Pharmacotherapy. 14(6). 699–706. 12 indexed citations

Fabi, Alessandra, Anna Di Benedetto, Giulio Metro, et al.. (2011). HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. Clinical Cancer Research. 17(7). 2055–2064. 72 indexed citations

Cuppone, Federica, Emilio Bria, Vanja Vaccaro, et al.. (2011). Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. Journal of Experimental & Clinical Cancer Research. 30(1). 54–54. 27 indexed citations

Metro, Giulio, Jennifer Foglietta, Michelangelo Russillo, et al.. (2010). Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Annals of Oncology. 22(3). 625–630. 120 indexed citations

Metro, Giulio, Diana Giannarelli, Gaetano Lanzetta, et al.. (2009). Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer. The Breast Journal. 16(1). 66–72. 10 indexed citations

Metro, Giulio, Alessandra Fabi, Michelangelo Russillo, et al.. (2008). Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.. PubMed. 28(2B). 1245–58. 8 indexed citations

10.

Fabi, Alessandra, Giulio Metro, G. Ferretti, et al.. (2008). Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. The Breast. 17(5). 499–505. 42 indexed citations

11.

Ferretti, G., Alessandra Felici, Paola Papaldo, Alessandra Fabi, & Francesco Cognetti. (2007). HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Current Opinion in Obstetrics & Gynecology. 19(1). 56–62. 83 indexed citations

12.

Carlini, Paolo, Andrea Michelotti, G. Ferretti, et al.. (2007). Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients. Cancer Investigation. 25(2). 102–105. 33 indexed citations

13.

Gasparini, Giampietro, Massimo Gion, Luigi Mariani, et al.. (2006). Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Research and Treatment. 101(3). 355–365. 107 indexed citations

14.

Ferretti, G., Emilio Bria, Diana Giannarelli, et al.. (2006). Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. Thrombosis Research. 119(4). 525–529. 2 indexed citations

15.

Papaldo, Paola, Alessandra Fabi, G. Ferretti, et al.. (2006). A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Annals of Oncology. 17(4). 630–636. 56 indexed citations

16.

Papaldo, Paola, Serena Di Cosimo, G. Ferretti, et al.. (2005). Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. The Breast. 15(2). 269–272. 1 indexed citations

17.

Carlini, Paolo, G. Ferretti, Serena Di Cosimo, et al.. (2003). Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?. The Journal of Steroid Biochemistry and Molecular Biology. 86(1). 107–109. 10 indexed citations

18.

Cosimo, Serena Di, G. Ferretti, Nicola Fazio, et al.. (2003). Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials. Acta Oncologica. 42(7). 693–700. 17 indexed citations

19.

Ferraresi, Virginia, Michèle Milella, Angela Vaccaro, et al.. (2000). Toxicity and Activity of Docetaxel in Anthracycline-Pretreated Breast Cancer Patients. American Journal of Clinical Oncology. 23(2). 132–139. 30 indexed citations

20.

Lauro, Luigi Di, et al.. (1986). Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.. PubMed. 70(7). 911–2. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact